Abstract |
Clinical and bacteriological efficacy ofjosamycin (Vilprafen), a macrolide antibiotic, was studied in 30 out- and inpatients at the age of 18 to 68 years (the average of 43.4+/-16.7 years old) with nonsevere (PORT) community-acquired pneumonia in the case histories. Josamycin was administered orally in a dose of 500 mg every 8 hours for 7 to 10 days. The treatment course was 5 to 10 days (the average of 7.7+/-1.3 days). The recovery was stated in 28 (93.3%) patients and the pathogen eradication was recorded in 16 (88.9%) patients. Moderate side effects not requiring discontinuation of the drug use were observed in 3 patients. The results of the treatment were indicative of the josamycin high efficacy in the treatment of the patients with nonsevere community-acquired pneumonia.
|
Authors | S V Iakovlev, M A Aleksandrova, M P Suvorova, S A Kostina |
Journal | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]
(Antibiot Khimioter)
Vol. 51
Issue 3-4
Pg. 47-8, 50-2
( 2006)
ISSN: 0235-2990 [Print] Russia (Federation) |
PMID | 17165259
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Josamycin
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-Bacterial Agents
(administration & dosage, adverse effects, therapeutic use)
- Community-Acquired Infections
(drug therapy, etiology)
- Evaluation Studies as Topic
- Female
- Gram-Negative Bacteria
(isolation & purification)
- Gram-Positive Bacteria
(isolation & purification)
- Humans
- Josamycin
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Prospective Studies
|